Lakewood-Amedex Biotherapeutics Inc. - Common Stock (LABT)

Lakewood-Amedex Biotherapeutics Inc. today announced that Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, has issued a Letter to Shareholders highlighting the Company's recent clinical, corporate and financial achievements and outlook as it advances Nu-3 into Phase 2 clinical development.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

As investors continue searching for emerging growth opportunities, several technology, biotechnology, healthcare, industrial automation, and digital infrastructure companies trading under $2 are attracting attention following recent corporate developments spanning Artificial Intelligence (AI), AI Infrastructure, Robotics, Healthcare Technology, Graphene, and Advanced Manufacturing.

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com